LGALS1 and myeloid neoplasm: We demonstrate the utility of the dataset in identifying clinically-actionable targets by focusing on galectin-1, a β-galactoside binding protein that has been previously implicated in cancer, tissue fibrosis and immunoregulation (56, 57) although its role in myeloid malignancies has not been fully investigated.